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Selenite induces apoptosis in sarcomatoid malignant mesothelioma 
cells through oxidative stress 
 
Abstract 
 Malignant mesothelioma cells differentiate into sarcomatoid or epithelioid 
phenotypes. The sarcomatoid cell type is more resistant to chemotherapy and yields a 
worse prognosis. We have investigated whether selenite alone and in combination with 
doxorubicin induced apoptosis in variously differentiated mesothelioma cells. Selenite in 
concentrations that could potentially be administered to patients strongly inhibited the 
growth of the sarcomatoid mesothelioma cells (IC 50 = 7.5 µM), whereas epithelioid 
cells were more sensitive to doxorubicin. Benign mesothelial cells remained largely 
unaffected. Selenite potentiates doxorubicin treatment.. Apoptosis was the dominating 
mode of cell death. The toxicity of selenite was mediated by oxidative stress. 
Furthermore the activity of the thioredoxin system was directly dependent on the 
concentration of selenite. This offers a possible mechanism of action of selenite 
treatment. Our findings suggest that selenite is a promising new drug for the treatment of 
malignant mesothelioma.  
 
Keywords: mesothelioma, phenotype, drug-resistance, apoptosis, selenium, thioredoxin 
reductase.
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Introduction 
 Malignant mesothelioma is a tumor arising from mesothelial cells following 
asbestos exposure. The tumor is aggressive and highly resistant to chemotherapy. 
Mesothelioma cells may differentiate into an epithelioid or a sarcomatoid phenotype. 
Presence of sarcomatoid cells in the tumor correlates to a poor prognosis. Furthermore, a 
survival advantage for patients receiving surgery and adjuvant chemotherapy has been 
confirmed only in patients with epithelioid morphology, and such therapy had no impact 
on survival in patients with sarcomatoid mesothelioma [1]. The ability of mesothelioma 
cells to differentiate into these two phenotypes has been retained in the cell lines STAV-
AB (epithelioid) and STAV-FCS (sarcomatoid). Both sub-lines are derived from the 
same tumor, and their growth patterns depend on the serum composition [2]. 
 A detailed and systematic molecular screening approach, based on suppression 
subtractive hybridization (SSH) and DNA array analyses, has uncovered important 
differences in the molecular basis of mesothelioma differentiation [3, 4]. Some of these 
differences may be further explored for therapeutical purposes. In particular, the 
thioredoxin system is highly upregulated in both STAV cell lines, with the epithelioid 
STAV-AB cells having the highest amounts of thioredoxin reductase-1 (TrxR1) reported 
so far [3]. Overexpression of thioredoxin 1 (Trx1) in malignant mesothelioma has also 
been reported using cDNA and mRNA microarray [5-7], and malignant mesothelioma 
tissue biopsies show immunoreactivity to both these proteins[8]. 
 The thioredoxin system comprises Trx1, TrxR1, and NADPH. This system has 
the capacity to reduce protein disulfides in general. It plays an important role in the 
regulation of the redox balance in the cell, associating e.g. apoptosis to redox 
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mechanisms. TrxR1 is a key enzyme in selenium metabolism [9, 10] that generates 
indispensable selenium substrates for the synthesis of all selenoproteins. Glutathione 
peroxidase (GPx) is also a selenoenzyme with an important antioxidant role in the cell. 
 It has been hypothesized that one carcinogenic effect of asbestos is due to 
generation of reactive oxygen species. The exceptionally high expression of TrxR1 in 
mesothelioma cell lines indicates that the enhanced ability to maintain cellular redox 
status may give a survival advantage for transformed mesothelial cells. The modulation 
of cellular redox status thus emerges as a target for drug action. 
 This study aimed to investigate the consequences of altered redox balance on 
the viability of mesothelioma cells. We studied the effects of selenite, alone or in 
comparison with doxorubicin, measuring the viability of variously differentiated 
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Materials and methods 
Chemicals 
 Selenite (Na2SeO3), Tris-HCl, EDTA, HEPES, DMSO, sodium azide (NaN3), 
H2O2, 5,5´dithiobis (nitrobenzoic acid) (DTNB), guanidine-HCl, bovine serum albumin, 
sodium deoxycholate (NaDOC), Biuret reagent, Glutathione (GSH), insulin from bovine 
pancreas, ascorbic acid, 2, 7-dichlorodihydrofluorescein diacetate (DCF) and NADPH 
were all purchased from Sigma (St. Louis, USA). Doxorubicin (Adriamycin®) was 
obtained from Pharmacia & Upjohn (Stockholm, Sweden). Baker´s yeast glutathione 
reductase (GR) and DCFH-DA (5(6)-Carboxy-2’,7’ -dichlorofluorescein diacetate) was 
obtained from Fluka (Buchs, Switzerland). E. coli Trx1 was purchased from Promega 
(Leiden, the Netherlands). The specific antibody to Trx1 was obtained from IMCO 
Corporation (Stockholm, Sweden), and the anti-TrxR1 antibody was purchased from 
Upstate Biotechnology (NY, USA). WST-1 colorimetric reagent was obtained from 
Roche (Penzberg, Germany). Gentamicin and RPMI 1640 medium was obtained from 
Invitrogen Corporation (Carlsbad, CA, USA). The Annexin V kit was obtained from 
Caltag Laboratories, (Burlingame, CA, USA).  
Cell culturing and characterization of growth pattern: 
 Experiments were performed on a well-established in vitro model of 
mesothelioma differentiation consisting of the two malignant mesothelioma cell sub-lines 
STAV-AB and STAV-FCS [11]. STAV-AB is grown in human AB serum and has 
epithelioid morphology, whereas STAV-FCS is grown in Fetal Calf Serum (FCS) and has 
sarcomatoid morphology (Fig. 1). Furthermore, we have included three other 
mesothelioma cell lines, two adenocarcinoma cell lines and two short-term cultures of 
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benign mesothelial cells. The M9K and M28K mesothelioma cell lines were kindly 
provided by Dr. K. Linnainmaa (Helsinki, Finland). The ZL34 mesothelioma cell line and 
the WART adenocarcinoma cell line were provided by Dr. J. Klominek (Huddinge, 
Sweden). The MCF7 breast cancer cell line was purchased from the American Type 
Culture Collection (ATCC, Rockville, MD, USA). The cultures of benign mesothelial 
cells were derived from cytological material sent to the laboratory for examination. The 
local ethical committee approved this study in accordance with the ethical standards of 
the Helsinki Declaration of 1975, as revised in 1983. 
 Tumor cells were cultivated in 75 cm2 flasks (Sarstedt, Newton, USA) in RPMI 
1640 medium supplemented with Gentamicin and 10% serum under conditions of 37ºC 
and 5% CO2.  Cell morphology was assessed by phase-contrast microscopic examination 
and immunostaining with two differentiation markers; vimentin and cytokeratin, as 
described by Dobra et al. [11], verifying the preserved differences in phenotype. For 
analysis of levels of reactive oxygen species, cells were grown directly on glass slides, 
and the experiment was performed at 80% confluence. 
Assay of cytotoxicity:  
 The WST-1 colorimetric reagent was used to measure cell viability. This 
reagent is cleaved by mitochondrial enzymes in living cells. The cleavage products are 
fluorescent at 450 nm. Samples were analysed in a microplate reader, the fluorescence at 
650 nm was measured and subtracted from that at 450 nm to compensate for differences 
in background absorbance. 
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The effect of doxorubicin, selenite and their combination on the in vitro growth of 
mesothelioma cells with various differentiations was determined using the STAV-AB and 
STAV-FCS cell lines. The cells were distributed on 96-well microplates with an equal 
number of approx. 40,000 cells in each well. They were then incubated for up to 76 h 
with selenite and/or doxorubicin. Measurements of cytotoxicity were made at 24-hour 
intervals, starting at 4 h. Initially experiments were conducted with selenite 
concentrations of 1, 2.5, 5, 10, and 30 µM. IC 50 was calculated from the obtained dose 
response curve. Similarly, doxorubicin was tested in concentrations of 0.2, 0.6, and 1.2 
µg/ml, corresponding to 0.33, 1 and 2 µM, respectively [12].  
 Based on results of these trials, an experiment was set up where the cells were 
incubated with combinations of 5 and 10 µM of selenite and 0.2 and 0.6 µg/ml of 
doxorubicin, as well as an untreated control. All experiments were carried out three times 
in quadruplicate. 
 To investigate whether the cytotoxic effect of selenite could be abrogated by an 
antioxidant, cells were treated with 7,5 µM of selenite using the same procedure as 
described above, and ascorbic acid was added in concentrations ranging between 0 µM 
and 1 mM. 
Assessment of apoptosis:  
 STAV-FCS and STAV-AB cells were distributed in equal amounts of approx. 
450,000 in 25 cm2 flasks (Sarstedt, Newton, USA) and incubated with 1, 5, 10 and 30 µM of 
selenite. Cells were harvested after 24 and 48 hours and subjected to morphological 
examination and FACS analysis. Similarly, cells of both sub lines were treated with 5 and 10 
µM of selenite combined with 0.2 and 0.6 µg/ml of doxorubicin. After 24 and 48 h, the cells 
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were harvested and analyzed independently using morphological methods and FACS-
analysis, and compared to an untreated control population.  Both experiments were repeated 
three times.  
 i.) Morphological examination - For every concentration, two cytospin preparations 
were made. Slides were allowed to dry and thereafter fixed for 30 seconds in 100% acetone 
followed by 10 min in 99.5% ethanol. After fixation, cells were stained with Giemsa dye.  
All slides were randomized and examined morphologically in a double-blind manner. 
Pyknosis (karyopyknosis) was defined as shrunken nuclei and condensation of the nuclear 
chromatin, indicating that the cells undergo programmed cell death.  The pyknotic index was 
determined as the percentage of cells with pyknotic nuclei. Cells with more than one nucleus 
or without cytoplasm were not counted. 
 ii.) Fluorescence-activated cell sorting (FACS) - FACS examination was conducted 
using the Annexin V/Propidium Iodide (PI) analysis. Annexin V labels cells that demonstrate 
externalisation of phosphatidylserine on the plasma membrane, as an early sign of apoptosis. 
The parallel staining with propidium iodide (PI) labels those cells that have increased 
permeability of the cell membrane, as a sign of cell decay. This represents a later phase of 
apoptosis. When the dying cells begin to disintegrate, it is not possible to distinguish 
between apoptotic and necrotic cells using this analysis.  
 The procedure was carried out according to the manufacturer’s instructions. 
Briefly, 105 cells were pelleted, washed twice with PBS and resuspended in 100 µl Annex-B 
binding buffer. 5 µl of Annexin V and 5 µl of PI were added followed by incubation in the 
dark for 25 min. 400 µl Annex-B were added and the samples were immediately analyzed on 
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a FACS cytometer (Becton Dickinson, Mountain View, CA, USA), using the Cell Quest 
software. 
Enzyme activity analysis: 
 Preparation of cell homogenates – Cell pellets were resuspended in a buffer (50 
mM Tris-HCl, pH 7.6 and 1 mM EDTA) while kept on ice, followed by sonication and 
centrifugation at 25’000  g for 10 min at 2oC. The supernatants were transferred to new 
tubes for enzyme activity measurements. The protein concentrations in the cell 
homogenates were determined by the Biuret method [13]. 
 TrxR1 enzyme activity assay - The TrxR1 enzyme activity in the cell 
homogenates was measured through a coupled reaction according to Holmgren and 
Björnstedt [14]. From each homogenate 100 µg protein was incubated with 80 mM 
HEPES (pH 7.5), 0.9 mg/ml NADPH, 6 mM EDTA, 2 mg/ml insulin, and 10 µM E.coli 
Trx1 at 37 C for 20 minutes in a final volume of 120 µl. The reaction was terminated by 
the addition of 500 µl DTNB (0.4 mg/ml) with 6 M guanidine-HCl in 0.2 M Tris-HCl pH 
8.0. The absorbance at 412 nm was measured within 20 min. The TrxR1 in the cell 
homogenates, using NADPH as a cofactor, reduced the oxidized Trx1 added. The 
reduced Trx1 then spontaneously reduced disulfides in insulin. The dithiols formed in 
insulin was visualized by the addition of DTNB. DTNB was reduced to D- and TNB+ by 
the dithiols formed in insulin.  
 GPx enzyme activity assay - The GPx enzyme activity was measured through a 
coupled reaction described by Lawrence and Burk [15]. A modified protocol was created 
to fit a 96 well plate. 100 µg protein from each cell homogenate was incubated for 3 min 
at 25 C with 0.1 M Tris-HCl buffer (pH 7.6), 2 mM EDTA, 2 mM NaN3, 4 mM GSH, 10 
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units of GR and 0.8 mM NADPH in a total volume of 195 µl. After the incubation 5 µl of 
the reagent H2O2 was added to a concentration of 10 mM as a substrate for the GPx 
enzyme. The GPx reduced H2O2 to H2O by oxidizing two GSH into GSSG. GR then 
reduce GSSG into two GSH again oxidizing NADPH, the oxidation of NADPH into 
NADP+ was measured kinetically at 340nm as an indirect measure of the GPx activity.  
 Measurement of cellular redox status – For in vivo detection of intracellular 
reactive oxygen species (ROS) induction, the fluorescent probe 2, 7-
dichlorodihydrofluorescein diacetate (DCF) was used. Cells were exposed to 5, 7.5 and 
21 M selenite for various times (4, 8, and 12h), followed by 15 min incubation in the 
presence of 10 M DCFH-DA probe, dissolved in a small volume of DMSO. The 
induction of ROS was monitored qualitatively by confocal laser microscopy. The 
excitation and emission wavelengths were 488 and 568 nm, respectively. Cells stimulated 
with 0.1 M H2O2 were used as positive controls.     
 Immunocyto- and histochemical analysis of the expression of Trx1 and TrxR1 – 
Cytological preparations were performed on 15 pleural effusions, comprising 5 malignant 
mesotheliomas, 5 adenocarcinomas and 5 benign mesothelial proliferations. 
Immunocytochemical reactions were performed on air-dried, acetone- and 95% ethanol-
fixed cytospin preparations. Immunohistochemical analysis was performed on 9 native 
biphasic malignant mesothelioma tissue specimens from our mesothelioma bank, 
sampled by Dejmek et al. [16]. The histological sections were routinely processed, 
formalin fixed and paraffin-embedded.  
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Antigen retrieval was performed in 10mM sodium citrate buffer, pH 6.0 at 95oC. 
Endogenous peroxidase activity was abolished by 0.6-0.75 % H2O2 in methanol for 30 
minutes and non-specific binding of antibodies was blocked by 3% normal rabbit or 
mouse serum. The cells were then incubated with specific antibodies to Trx1 (1:50), and 
to TrxR1 (1:100), respectively. Antigen-antibody reaction products were visualized with 
the streptavidin-biotin-peroxidase method with diaminobenzidine as substrate-chromogen 
(ChemMate Detection Kit, DAKO).  
 Negative controls were obtained by using the specific antibodies after pre-
incubation with excess amounts of Trx1 and TrxR1 proteins, respectively. All moderate 
or strong staining was evaluated as positive. Weak staining or focal reactivity in 
dispersed cells was considered as negative.  
Statistics 
 Data were evaluated by one-way ANOVA tests and Tukey-Kramer Honestly 
Significant Difference tests. The null hypothesis of no difference was rejected at a 
significance level of p<0.05. Confidence intervals for the pycnotic indices were 
calculated using the statistic (x-p)/ (p(1-p)/n).  
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Results 
Characterization of cells 
 The doubling time was comparable between the STAV AB and STAV FCS cell 
sub lines.- When the cells were harvested, they were carefully examined to ensure that 
the growth patterns remained epithelioid and sarcomatoid, respectively. STAV-AB 
cultures have a cobblestone appearance whereas STAV-FCS cells have a length:width 
ratio exceeding 2:1. Immunocytochemical analysis showed that the epithelioid STAV-AB 
cells were strongly reactive to cytokeratin antibodies, but the vimentin staining 
dominated in the fibroblast-like STAV-FCS cells.  
Doxorubicin selectively inhibits the growth of epithelioid but not sarcomatoid 
mesothelioma cells 
 To investigate the effect of doxorubicin on mesothelioma cells of epithelioid 
and sarcomatoid differentiation, the STAV-AB and STAV-FCS cell lines were treated 
with increasing doxorubicin concentrations (0.2-1.2 g/ml), and the number of viable 
cells was assayed after 28 and 52 hours. The epithelioid cells showed a dose- and time-
dependent growth inhibition. Already after 28 hours a significant reduction of cell 
viability was detected using 1.2 g/ml doxorubicin. These cells were increasingly growth 
inhibited after 52 hours (Fig. 2A). In contrast, the sarcomatoid cells did not respond to the 
treatment. The proliferation rate of these resistant cells rather seemed to increase when 
treated with the highest concentration of doxorubicin (1.2 g/ml), although the difference 
was not statistically significant (Fig. 2B). 
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Selenite inhibits the growth of both mesothelioma phenotypes in a dose- and time-
dependent manner 
 The effect of selenite on cell growth was assayed after 28 and 52 h, using 
concentrations ranging from 1-30 µM. Both the epithelioid and the sarcomatoid cell sub 
lines were inhibited when treated with 5-30 µM of selenite. The sarcomatoid cells were 
significantly more sensitive to lower selenite concentrations already after 28 h (Fig. 2C). 
IC 50 as determined after 28 h was 7.5 µM for the sarcomatoid cell line and 21 µM for 
the epithelioid cells. At 52 h, the pattern was similar and the inhibition was stronger (data 
not shown). At low doses (1-5 µM), transient growth stimulation was observed in both 
phenotypes. 
Several tumor cell lines respond well to selenite treatment, whereas benign mesothelial 
cells are less sensitive 
 To investigate whether the effects of selenite treatment could be generalized to 
other cancer cells, a cytotoxicity test was conducted on several other cell lines. We used 
three mesothelioma cell lines, two adenocarcinoma cell lines and two short-term cultures 
of benign mesothelial cells. They were treated for 24 and 48 h with 7.5 µM of selenite. 
Both adenocarcinomas were inhibited to less than 40% of control in 24 h, and one 
mesothelioma dropped to 5% of control. After 48 h, none of the malignant cell lines 
exceeded 5% of the viability of the controls. The benign mesothelial cells were growth 
stimulated at 24 h, and 69% or more, relative to control, remained viable after 48 h (Fig. 
2D). 
Selective induction of apoptosis in sarcomatoid mesotheliomas 
14 (36)  
Selenite potentiates the toxic effect of doxorubicin 
 Treatment with selenite and doxorubicin was combined to assess whether they 
have synergistic effects. This treatment inhibited epithelioid cells strongly. Although the 
effect was limited at 28 h, treatment with 0.2 or 0.6 µg/ml of doxorubicin combined with 
10 µM of selenite for 52 h caused a dramatic loss of viability. Treatment with the same 
concentrations of doxorubicin and 5 µM of selenite yielded viability ranging between 
20% and 40% of control (Fig. 2E). In contrast, sarcomatoid cells were inhibited already 
at 28 h. Of the cells treated with doxorubicin together with 5 or 10 µM of selenite, 
respectively, around 90% and 60% of the cells were still viable relative to control at 28 h, 
dropping to around 60% and 50% at 52 h (Fig. 2F). 
Selenite induces apoptosis in mesothelioma cells 
 STAV-AB and STAV-FCS cells were treated with increasing selenite 
concentrations and the amount of apoptotic cells was assessed by morphological 
investigation and by FACS analysis of Annexin-V positive cells. Morphological analysis 
shows significantly increased apoptosis, as judged from the proportion of pyknotic cells, at 
10 and 30 µM of selenite for the epithelioid cells (Fig. 3A) and at 5, 10 and 30 µM of 
selenite for the sarcomatoid cells (Fig. 3B). At 10 µM, the percentage of cells with apoptotic 
characteristics is close to 40% for both phenotypes. At 30 µM it increases to between 60% 
and 80%. Necrosis as judged morphologically by cell swelling and loss of chromatin patterns 
occurred in a small number of cells only and was completely subordinate to death by 
apoptosis. 
 FACS analysis shows that both the epithelial (Fig. 3 C) and the sarcomatoid (Fig. 3 
D) phenotypes undergo apoptosis in a time and dose dependent manner. The kinetics of the 
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apoptotic changes however differed substantially between the phenotypes. At 28 hours, the 
proportion of early apoptotic cells, corresponding to the lower right quadrant, was much 
higher in the sarcomatoid phenotype (Fig. 3 D) than in the epithelioid phenotype (Fig. 3 C). 
The sarcomatoid cells showed more advanced changes with a substantial proportion of cells 
in the upper right quadrant, corresponding to late apoptosis (Fig. 3D). At 52 hours, similar 
pattern of distribution of early and late apoptotic cell populations have developed also in the 
epithelioid cells. The morphological investigation of these late apoptotic or pyknotic cells, 
show a good correlation with the FACS analysis (Fig. 3).  
The combination of selenite and doxorubicin induces apoptosis in mesothelioma cells  
of both phenotypes 
 Both cell sub lines demonstrate significantly increased apoptosis, as measured 
morphologically, after treatment with 10 µM selenite and 0.6 or 1.2 µg/ml of doxorubicin at 
48 h. These samples had proportions of 6%-10% of apoptotic cells when judged 
morphologically. FACS analysis of PI uptake was not possible due to doxorubicin 
fluorescence.  When estimated from the binding of Annexin V, to the number of apoptotic 
cells was 44% among the epithelioid cells and 24% among the sarcomatoid cells. 
Selenite decreases TrxR1 and GPx activity 
 The activity and amount of TrxR1 and GPx were assayed using two different 
methods. Both cell lines have an exceptionally high expression of TrxR1. It is highest in 
the epithelioid cell line where it exceeds 12 µg/mg of total protein. When treated with 10 
µM selenite the activity decreased dramatically, reaching about 50% in the epithelioid 
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cells, and about 80% in the sarcomatoid cells. At 30 µM only a small fraction of the 
original activity was still detectable (Fig. 4A). 
 The activity of GPx was similar in the two phenotypes, and it increased when 
the cells proliferated in low concentrations of selenite. The activity was, however, 
inhibited already at 2.5 µM, the sarcomatoid cells being somewhat more sensitive than 
the epithelioid ones. At 10 and 30 µM the activity was less than 30% of the original 
levels (Fig. 4B). 
Selenite toxicity is mediated by oxidative stress 
 We determined the reactive oxygen species (ROS) generation in the presence or 
absence of selenite (Fig. 5a). Sarcomatoid mesothelioma cells exposed to selenite have 
shown a time and dose dependent increase in DCF fluorescence intensity compared to the 
untreated paternal cells. A differential effect of selenite was observed on the two cell 
phenotypes through the experiment, with selective ROS induction in the most resistant 
sarcomatous phenotype. In contrast, a reduction of DCF fluorescence intensity was 
observed in the epithelioid STAV-AB cell sub-line following selenite exposure. The 
toxicity of selenite could be completely reversed by the addition of ascorbic acid, which 
is an antioxidant (fig 6). 
Detection of Trx1 and TrxR1 in tumor specimens 
 The immunocytochemical investigation revealed strong to moderate 
immunoreactivity for both Trx1 and TrxR1 antibodies in malignant mesotheliomas and 
adenocarcinomas, whereas benign mesothelial cells were negative (Fig.7). However, 
reactive mesothelial cell samples displayed scattered cells with weak positive staining. 
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This corresponds well to a study by Kahlos et al. [8], where TrxR1 immunostaining could 
also not be demonstrated in benign mesothelium. 
 Immunohistochemical analysis on biphasic malignant mesothelioma tissue 
specimens showed profound differences in the TrxR1 protein levels of epithelioid and 
sarcomatous tumor components. Marked reactivity was noted in the epithelial component 
of all biphasic tumors (Fig. 8), but the spindle-shaped sarcomatous tumor components 
remained largely unstained.  
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Discussion 
 Malignant mesothelioma is a tumor that may exhibit two phenotypes – 
epithelioid and sarcomatoid – which seem to have different mechanisms for cancer 
progression [4] and respond differently to therapy. Presence of the sarcomatoid 
phenotype in a tumor is correlated to therapy resistance and a worse prognosis. 
Mesothelioma responds poorly and often only partially to treatment [17, 18], which may 
be explained by the tumor cell heterogeneity. Our previous molecular characterization 
reveals profound differences between the phenotypes [4]. This characterization makes it 
possible to find drug targets that are specific for the respective tumor component. One 
such possible target is the thioredoxin system, which is both abundantly and differentially 
expressed in the two mesothelioma phenotypes. 
 Treatment of malignant mesothelioma is most often based on a combination of 
several drugs. Doxorubicin is an anthracycline that is often included in such 
chemotherapy regimens. It has several mechanisms, one of which is the formation of free 
radicals, leading to oxidative stress [19]. High-dose doxorubicin causes excessive 
toxicity, particularly to the heart [20]. In this study, the sarcomatoid cells were resistant 
to doxorubicin, while the epithelioid cells were sensitive, which correlates well to both 
clinical experience [17, 18] and in vitro studies. IC 50 values of doxorubicin for 
mesothelioma cell lines ranging between 0.01 and 1.85 µM have been reported [21-24], 
and in comparison both our cell sub lines appear to be extraordinarily resistant. In fact, 
the sarcomatoid cells continued to proliferate when treated with the highest dose given (2 
µM). A similar result has been reported by Hedges et al [21]. For therapeutical purposes, 
serum doxorubicin concentrations ranging from approx. 0.025 to 2 µM are considered 
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useful [19], and cytotoxic effects on the sarcomatoid components would then not be 
expected. 
 In contrast with the above findings the otherwise therapy-resistant sarcomatoid 
cells were sensitive to selenite with a striking loss of viability (IC 50 = 7.5 µM), when 
selenite (SeO32-) was administered as a sodium salt. The epithelioid cells were not as 
sensitive (IC 50 = 21 µM). The effect of selenite was dose-dependent. We confirmed 
these results using three additional mesothelioma cell lines and two adenocarcinoma cell 
lines, all of which were highly sensitive when treated with 7.5 µM of selenite. In contrast, 
short-term cultures of benign mesothelium tolerated this concentration well. At lower 
concentrations we observed a transient growth stimulation, which may be a consequence 
of suboptimal amounts of selenium in standard cell culture conditions [25]. 
 We have shown that selenite induces the formation of ROS in the sarcomatoid 
cells, while in the epithelioid cells, with their higher levels of the thioredoxin system, this 
could not be seen by DCF labeling. It was possible to eliminate the toxic effect by the 
addition of an antioxidant (ascorbic acid) indicating that the cytotoxic effect of selenite is 
mediated by oxidative stress. This result is consistent with previous reports [26, 27]. 
Using independent methods we have also confirmed that the mode of cell death is 
apoptosis.  
 Selenite is a small ion that diffuses easily over plasma membranes to reach the 
intracellular compartment. In the presence of TrxR1 or thiol groups it is readily reduced 
into selenide (HSe-), which in the presence of oxygen undergoes redox cycling, causing 
rapid and massive non-stoichiometric oxidation of NADPH [28]. Furthermore, selenite 
may directly redox cycle with thiols to cause superoxide generation [29] and loss of 
Selective induction of apoptosis in sarcomatoid mesotheliomas 
20 (36)  
protein structure. Unbalanced generation of ROS such as superoxide will damage cellular 
constituents and induce apoptosis as a consequence [30]. The oxidation of thiols into 
disulfides may cause conformational changes in the affected proteins, which can render 
them unable to exert their normal function. This adds to the previously shown effects of 
selenium on mesothelioma cells related to the expression of Selenoprotein 15 (SEP15) 
[31], where cells expressing less SEP15 were less responsive to the effects of selenium. 
 Both malignant mesothelioma cell sub-lines used in this study express 
exceptionally high levels of TrxR1. The epithelioid cell line expresses twice as much as 
the sarcomatoid cell line. The mechanism of selenite toxicity is likely mediated in part by 
oxidation of thiols, with a resulting generation of ROS.  Selenite will oxidize thiol 
groups, and these will be regenerated by TrxR1. In doing so, the Trx1 will become 
oxidized. When oxidized, Trx1 causes release and activation of Apoptosis Signal 
Regulating Kinase 1 (ASK-1) [32].  
 On the other hand, a high level of TrxR1 or a capacity to induce the activity has 
recently been shown to correlate with cell survival after exposure to increasingly toxic 
levels of selenium [33-35], In the present study we show a similar correlation since the 
epithelioid cells were more resistant to selenite. The protective effect of TrxR1 is likely 
explained by three different mechanisms, namely detoxification of selenite by reduction 
to elementary selenium, restoring intracellular thiols lost in redox cycling, and the 
detoxification of ROS, also formed during redox cycling.  
 Intracellular thiols thus have a double-edged effect. In the context of selenite 
treatment, they may either protect or damage the cell, possibly depending on their amount 
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and forms. This hypothetical model for the actions of selenite and the thioredoxin system 
is summarized in Fig. 9.  
 
 When the cells were exposed to selenite, cell survival was seen in the cells with 
the highest levels of TrxR1 and GPx activity. The damaging effects of selenite were 
amplified by the dose-dependent decrease in activity of both these enzymes. The  
remaining level of TrxR1 and GPx activity correlated well to the decrease of cell 
viability.TrxR1 has several well-described prosurvival effects. The high levels seen in 
mesothelioma may reflect a functional adaptation to an adverse redox environment, 
leading to increased dependence on the function of this enzyme. These cells may 
therefore be more sensitive to a decreased activit of TrxR1. Similarly; the decrease in 
GPx activity caused by selenite may play a part in the cytotoxic effect. 
 Selenite treatment potentiated the toxic effect of  doxorubicin  and yielded a 
dramatic loss of viability in both cell types.  Due to the heteroscedastic distribution of 
data, we did not analyze whether there was a statistically significant synergism. This 
effect is likely explained in part by the decreased activity of TrxR1 induced by selenite, 
since a high activity of TrxR1 is protective against the cytotoxic effects of doxorubicin 
[36, 37]. 
 Overexpression of Trx1 has been reported in several mesothelioma cell lines 
using cDNA and mRNA microarray [5-7], and distinct immunohistochemical reactivities 
for Trx1 and TrxR1 are common in malignant mesothelioma cell lines and tumor biopsies 
[8]. It can then be expected that the described sensitivity to selenite is common in 
Selective induction of apoptosis in sarcomatoid mesotheliomas 
22 (36)  
malignant mesotheliomas, while the benign mesothelium remains unaffected by such 
treatment. 
 
 Selenium toxicity has been relatively well studied. The main symptoms of 
chronic toxicity are brittleness of hair and nails and garlic breath. Yang et al. have shown 
that symptoms of selenium toxicity may be experienced at blood concentrations ranging 
from 1.05 mg/l, corresponding to 13.3 µM, as measured by changes in the fingernails 
[38]. Recently published data [39] indicate that doses up to 3200 µg/day over long 
periods of time can be tolerated, although mild symptoms including dizziness, brittle 
nails and hair, and garlic breath were reported by a few of the participants is the study. 
Blood selenium concentrations exceeding the 7.5 µM that we have used can probably be 
maintained safely in patients in the course of cancer therapy. The specific toxicity of 
selenite has not been systematically studied in humans, and therefore titration of maximal 
tolerable dose (MTD) would be necessary before commencing treatment. Concentrations 
ranging up to around 2 µM may stimulate proliferation of tumor cells. Transient growth 
stimulation may thus be expected when commencing such therapy. It may therefore be 
advisable to combine selenite treatment with one or more antimitotic cytostatics. 
 We show that when selenite is administered in clinically tolerable 
concentrations to mesothelioma cell lines, it generates ROS, oxidizes thiols and decreases 
the activity of the thioredoxin system. Consequently, apoptosis signaling pathways are 
activated, most likely through the mitochondrial pathway and ASK-1 signaling. The 
result is a striking loss of viability, especially in cells of the doxorubicin-resistant 
sarcomatoid phenotype.  The selenium also seems to potentiate simultaneously 
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administered doxorubicin with effects also in the epithelioid cells. This is a promising 
path towards new therapeutic possibilities. 
 
Studies aiming at a detailed characterization of the selenite-induced apoptosis 
mechanisms are in progress at our laboratory. Furthermore, the hypothesis should be 
investigated using in vivo systems that allow analysis of a wide range of possible effects 
of selenium, for example on tumor vascularization. Clinical trials with the prospect of 
taking advantage of these effects are imminent. 
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Abbreviations  
AB   Human AB serum 
Adeno   Adenocarcinoma 
ASK-1   Apoptosis Signal Regulating Kinase 1 
DCF   2’, 7’-dichlorodihydrofluorescein diacetate 
DCFH-DA  5(6)-carboxy-2’, 7’-dichlorodihydrofluorescein diacetate 
DMSO   Dimethyl sulfoxide 
DTNB   5, 5’dithiobis(nitrobensoic acid) 
EDTA   Ethylenediaminetetraacetic acid 
FACS   Fluorescence Activated Cell Sorting 
FCS   Fetal Calf Serum 
GPx   Glutathione Peroxidase 
GR   Glutathione Reductase 
GSH   Glutathione (reduced) 
GSSG   Glutathione (oxidized) 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
MM   Malignant mesothelioma 
NaDOC   Sodium Deoxycholate 
PI   Propidium Iodide 
ROS   Reactive Oxygen Species 
SD   Standard Deviation 
SEM   Standard Error of the Mean 
SEP15   Selenoprotein 15 
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Trx1   Thioredoxin 1 
TrxR1   Thioredoxin Reductase 1 
WST-1   Cell Proliferation Reagent 
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Figure legends 
 
Figure 1. Phase contrast photomicrographs depicting the STAV-AB mesothelioma cells 
with epithelioid morphology (A) and the STAV-FCS mesothelioma cells with 
sarcomatoid morphology (B) (bar = 50 m).  
 
Figure 2. Effects of selenite and doxorubicin on cell viability. Treatment with 
doxorubicin shows a dose and time dependent inhibitory effect on epithelioid (A) but not 
sarcomatoid (B) mesothelioma cells. Asterisks denote a statistically significant difference 
from the cells treated with the lowest dose (0,2 µg/ml). The dose-response curve for 
selenite (C) indicates sensitivity of both mesothelioma phenotypes after 28 h, the effects 
being more pronounced in the sarcomatoid cells. Asterisks denote a statistically 
significant difference between phenotypes. The response to 7,5 µM of selenite was 
similar in three other three mesothelioma cell lines (MM) and two adenocarcinoma cell 
lines (Adeno), while the benign mesothelial cells remained unaffected (D). Asterisks 
denote a statistically significant difference from both populations of benign mesothelial 
cells. The combination of selenite and doxorubicin inhibited both epithelioid (E) and 
sarcomatoid (F) mesothelioma cells. Asterisks denote a statistically significant difference 
from the untreated control (not shown in the diagram). Error bars show the standard error 
of the mean (SEM). 
 
Figure 3. Selenite induces apoptosis in mesothelioma cells. The morphological 
examination and FACS analysis of apoptosis correlate.  Morphological determination of 
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apoptosis in relation to concentration of selenite is shown in epithelioid (A) and 
sarcomatoid cells (B). Asterisks denote a significant difference from untreated cells. The 
proportion of apoptotic cells, as estimated from pyknotic index, was dose dependent with 
higher sensitivity to selenite in sarcomatoid (B) cells than in epithelioid ones (A). 
Apoptosis could also be demonstrated with a similar dose dependence by FACS analysis 
(C, D). The Y-axis depicts the fluorescence intensity of propidium iodide (PI) and the X-
axis the log of fluorescence intensity of Annexin V. Dose and time dependent increase of 
the apoptotic cells can be observed in both phenotypes (C, D). The epithelioid cell 
population shows signs of early apoptosis (lower right quadrant) in a substantial 
proportion of cells only after 52 hours (C), whereas the sarcomatoid cells are apopotic 
already after 28 hours (D). The cells in the upper right quadrant are late apoptotic and 
correspond very well to the proportion of pyknotic cells in morphological examination in 
both the epithelioid (A, C) and sarcomatoid (B, D) phenotypes. As nearly no 
morphological signs of necrosis were visible, we consider the cells in the upper right 
quadrant for the most part to be in a later phase of apoptosis.  
 
Figure 4. Selenite treatment decreases the thioredoxin reductase 1 (TrxR1) activity (A) 
and the glutathione peroxidase (GPx) activity (B), in cells of the two mesothelioma 
phenotypes. The cells were grown for 48 hours in culture medium, and supplemented 
with different concentrations of selenite for 48 hours. 
 
Figure 5. ROS generation by selenite in malignant mesothelioma cells. Representative 
micrographs showing untreated controls of sarcomatous STAV FCS cells (A), STAV 
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FCS cells treated with 5 µM selenite (B), untreated controls of epithelioid STAV AB 
cells (C), and STAV AB cells treated with 5 µM selenite (D). In the STAV FCS cells, 
selenite generates ROS. The converse effect appears in the STAV AB cells. 
 
Figure 6. The toxic effect of 7.5 µM selenite was abrogated by 1 mM ascorbic acid, 
indicating that the toxicity of selenite is mediated by oxidative stress. Asterisks denote a 
significant difference between cells treated with selenite and ascorbic acid and cells 
treated with only selenite. Data from one representative experiment are shown. 
 
Figure 7. Representative photomicrographs showing immunocytochemical staining for 
Trx1 (left column) and TrxR1 (right column) in cells exfoliated into pleural effusions. 
Malignant mesothelioma (A, B) and adenocarcinoma (C, D) cells demonstrated reactivity 
to both epitopes, while benign mesothelial cells (E, F) remained negative. Pre-incubation 
of antibodies with excess amounts of Trx1 (G) or TrxR1 (H) protein completely 
abolished all binding of antibodies to the tumor cells (bar = 50 m).  
 
Figure 8. Immunohistochemical staining for Trx1 (A, C) and TrxR1 (B, D) in vivo in 
biphasic mesothelioma, demonstrating that the enzyme is present in native tumor tissue. 
The biphasic mesothelioma tissue specimen show marked reactivity to Trx1 and TrxR1 in 
the epithelial tumor component while the spindle shaped sarcomatoid tumor components 
remained largely unstained (bar = 50 m). The images are representative for 9 sampled 
tumor specimens. 
 
Selective induction of apoptosis in sarcomatoid mesotheliomas 
36 (36)  
Figure 9.  Hypothetical model for the cytotoxic effects of selenium. The metabolic 
product selenide (HSe-) will redox cycle with thiols (R-SH) to generate massive non-
stoichiometric amounts of reactive oxygen species (ROS). The redox cycling is increased 
by free thiols and consumes NADPH. The formation of ROS will cause oxidative stress 
that damages the cell and is a direct cause for apoptosis. It will also oxidize thiols (R-SH) 
into disulfides (R-SS-R), thereby creating new covalent bonds within and between 
proteins. The tertiary structure of the affected proteins will change and they may be 
unable to maintain their function. Thioredoxin 1 (Trx1) reduces disulfides back into thiol 
groups in a redox cycle that is catalyzed by TrxR1 and consumes NADPH. Apoptosis 
Signal Regulating Kinase 1 (ASK-1) is a regulatory protein, which is inactive when 
bound to reduced Trx1. A shift towards oxidized Trx1 will lead to the release and 
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